Drug Profile

LBS 020

Alternative Names: LBS-020; Recombinant lubricin - Lubris Biopharma

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 May 2023 No recent reports of development identified for preclinical development in Xerostomia in USA (PO)
01 Aug 2022 No development reported - Phase-II for Xerostomia in Australia (PO) (Lubris BioPharma pipeline, July 2022)
27 Apr 2020 306571 - CTP push: [updated intro, KDM, added DCs and MoA, Thes req to be sent, updated dev table, created trial completion HE]

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com